AIM ImmunoTech Inc. (LON:0A4Y)
London flag London · Delayed Price · Currency is GBP · Price in USD
0.8215
-0.1735 (-17.44%)
At close: Feb 11, 2026

AIM ImmunoTech Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.

The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.

AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc.
CountryUnited States
Founded1966
IndustryBiological Products, Except Diagnostic Substances
Employees23
CEOThomas Equels

Contact Details

Address:
2117 SW Highway 484
Ocala, Florida 34473
United States
Phone352 448 7797
Websiteaimimmuno.com

Stock Details

Ticker Symbol0A4Y
ExchangeLondon Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
Thomas K. Equels Esq., J.D., M.S.Executive Vice Chairman, Chief Executive Officer and President
Robert Dickey IVChief Financial Officer
Peter W. Rodino III, Esq., J.D.Chief Operating Officer, Executive Director of Governmental Relations, General Counsel and Secretary
Ann Marie E. CoverlyDirector of Administration and Human Resources and Deputy Investor Relations Coordinator
Dr. Christopher Nicodemus FACP, M.D.Member of Scientific Advisory Board and Consulting Science Officer